Baheya Foundation explores AI to predict response to breast cancer treatment
The Egyptian non-profit has teamed up with GE Healthcare to utilise AI to assess how well a patient is responding to neoadjuvant therapy, commonly used prior to surgery. (Source: mobihealthnews)
Source: mobihealthnews - February 14, 2022 Category: Information Technology Source Type: news
Neoadjuvant Pembrolizumab Plus Chemo Treats Early TNBC
Rate of event - free survival higher with neoadjuvant pembrolizumab plus chemo versus chemo alone for early triple - negative breast cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 10, 2022 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Journal, Source Type: news
Neoadjuvant Pembrolizumab Plus Chemo Treats Early TNBC
THURSDAY, Feb. 10, 2022 -- For patients with previously untreated stage II or III triple-negative breast cancer, the rate of event-free survival is higher for those receiving neoadjuvant pembrolizumab combined with chemotherapy versus neoadjuvant... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 10, 2022 Category: Pharmaceuticals Source Type: news
Prehabilitation Exercise Intervention Studied in Esophageal Cancer
Structured prehabilitation exercise during neoadjuvant chemotherapy and surgery may enhance treatment response (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 2, 2022 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Surgery, Journal, Source Type: news
Prehabilitation Exercise Intervention Studied in Esophageal Cancer
WEDNESDAY, Feb. 2, 2022 -- For patients with esophageal cancer, a structured prehabilitation exercise intervention during neoadjuvant chemotherapy and surgery may enhance tumor regression and downstaging in response to treatment, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 2, 2022 Category: Pharmaceuticals Source Type: news
Surprise Finding: Prehabilitation Exercise Shrinks Tumor Surprise Finding: Prehabilitation Exercise Shrinks Tumor
Patients with esophageal cancer who followed a structured exercise program during neoadjuvant chemotherapy showed significant tumor shrinkage.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 2, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Adding ADT to Radiotherapy Ups Mets - Free Survival in Prostate Cancer
In meta - analysis, adjuvant ADT prolongation also linked to improvement in metastasis - free survival, but not neoadjuvant ADT extension (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 1, 2022 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Radiology, Urology, Journal, Source Type: news
No Benefit to Adding Trastuzumab for HER2 Esophageal Cancer No Benefit to Adding Trastuzumab for HER2 Esophageal Cancer
In patients with HER2-overexpressing esophageal cancer, adding trastuzumab to neoadjuvant chemoradiation was not effective in a phase 3 trial.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 28, 2022 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news
Neoadjuvant Cemiplimab Promising for Resectable Liver Cancer Neoadjuvant Cemiplimab Promising for Resectable Liver Cancer
Neoadjuvant cemiplimab induced pathological responses in one third of patients with resectable hepatocellular carcinoma in an ongoing phase 2 trial.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 28, 2022 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news
What's the Best Treatment Modality for Resectable Stomach Cancer? What's the Best Treatment Modality for Resectable Stomach Cancer?
For resectable gastric cancer, neoadjuvant chemoradiation may be better than other treatment modalities for achieving pathologic complete response, according to a new analysis.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - December 29, 2021 Category: Surgery Tags: Hematology-Oncology News Source Type: news
Early Data Support Neoadjuvant Immunotherapy for NSCLC Early Data Support Neoadjuvant Immunotherapy for NSCLC
A handful of studies on neoadjuvant immunotherapy for lung cancer are nearing completion, Mark Kris reports.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 22, 2021 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
Phase II study of Roche ’s giredestrant meets primary endpoint in the most frequently diagnosed type of breast cancer
Basel, 10 December 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase II coopERA Breast Cancer study met its primary endpoint in the neoadjuvant treatment of early stage ER-positive, HER2-negative breast cancer. Breast cancer is the most frequently diagnosed type of cancer, with major societal impac t.2 Hormone receptor (HR)-positive breast cancer is the most common subtype, representing ~70% of all diagnoses, or an estimated 1.6 million cases annually across the world.2,3 (Source: Roche Investor Update)
Source: Roche Investor Update - December 10, 2021 Category: Pharmaceuticals Source Type: news
Clinical Trials Lead to Promising Updates in Mesothelioma Immunotherapy
This study recruited patients with unresectable pleural mesothelioma who had not received prior chemotherapy.
The primary endpoint of median overall survival was significantly longer with the addition of bevacizumab to chemotherapy at 18.8 months versus 16.1 months with chemotherapy alone. However, adverse events such as hypertension and bleeding were more common in the bevacizumab group.
More recently, studies such as the phase II RAMSES trial in 2020 have shown promising results for combining anti-VEGF medication with chemotherapy as a second-line treatment. The addition of the VEGF inhibitor ramucirumab significan...
Source: Asbestos and Mesothelioma News - December 8, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
Timing Is Crucial: Sooner Is Better for Rectal Cancer Surgery Timing Is Crucial: Sooner Is Better for Rectal Cancer Surgery
Survival outcomes are considerably better for patients with rectal cancer who have surgery within 8 weeks or less after not responding to neoadjuvant chemoradiation.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 7, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Virtual Symposium to Focus on Mesothelioma Treatment Advances
Sylvester Comprehensive Cancer Center of South Florida will host its free virtual First Miami International Mesothelioma Symposium on November 6, 2021.
The Mesothelioma Program at the Sylvester Comprehensive Cancer Center has grown to become one of America’s leaders in this specialized field, attracting a wide range of expertise for its upcoming virtual symposium.
“Mesothelioma is such a rare disease that we really have to bring in experts from around the world to get a true picture of what’s coming next. And I think we’ve done that with our program,” medical oncologist Dr. Estelamari Rodriguez, Symposium c...
Source: Asbestos and Mesothelioma News - October 5, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news
